Apoptotic pathway (indirect modulation)

The apoptotic pathway (indirect modulation) refers to the therapeutic strategy of inducing programmed cell death by targeting regulatory networks rather than the core apoptotic machinery itself (Pfeffer & Singh, 2018). Apoptosis is a fundamental biological process used by multicellular organisms to eliminate redundant or potentially harmful cells, and its dysregulation is a hallmark of various diseases, particularly cancer (Fuchs & Steller, 2011). While direct modulators target proteins like BCL-2 or Caspases, indirect modulators act on upstream signaling pathways, such as the PI3K/AKT/mTOR pathway or epigenetic regulators, to restore the cell's natural ability to undergo suicide (NCI Drug Dictionary). This broad category includes diverse drug classes like proteasome inhibitors (e.g., Bortezomib) and kinase inhibitors (e.g., Imatinib), which ultimately trigger the intrinsic or extrinsic apoptotic cascades (FDA, 2023). By disrupting oncogenic signaling or stress-response pathways, these drugs eventually lead to the activation of caspases and the systematic dismantling of the cell. Because this term describes a collective biological mechanism involving numerous distinct proteins across various families, it is classified as a pathway-level description rather than a discrete, individual molecular target.

Other names

Programmed cell death pathway modulationIndirect apoptosis inductionApoptosis signaling network

Indirect modulation of apoptosis involves the inhibition of survival signaling pathways (e.g., PI3K/AKT, BCR-ABL) or the disruption of cellular homeostasis (e.g., proteasome inhibition), which shifts the balance of BCL-2 family proteins to favor the activation of the intrinsic or extrinsic apoptotic cascades (Pfeffer & Singh, 2018; Fuchs & Steller, 2011).